Oravax Medical, a new venture from Israeli firm Oramed Pharmaceuticals and India's Premas Biotech, is preparing to launch Phase 1 clinical trials this summer for its oral COVID-19 vaccine pill.
This innovative pill-form candidate is designed to protect against emerging coronavirus mutations. In preclinical animal studies, it elicited strong systemic immunity via immunoglobulin G (IgG), prevalent in blood and fluids for viral protection, and mucosal immunity through immunoglobulin A (IgA).
Building on these promising results, Oravax plans to initiate human trials in Q2. Successful development could enable needle-free, at-home vaccination, streamlining mass immunization and logistics.
"An oral vaccine removes key barriers, empowering self-administration at home," says Nadav Kidron, CEO of Oramed. "With potential annual boosters like flu shots, ease of use will be crucial."
This "second-generation" approach offers simpler administration and distribution—no cold chain required beyond standard refrigeration, followed by room-temperature storage.
Professor Paul Hunter of the University of East Anglia notes caution: "Rigorous studies are essential to validate efficacy." He adds, "They could benefit needle-phobic individuals and speed up delivery."
Other next-gen options under study include nasal sprays and skin patches.
Meanwhile, vaccination drives intensify worldwide. In France, amid rising ICU cases, Health Minister Olivier Véran announced military and firefighter support for at least 35 major "vaccinodromes" starting in April to vaccinate millions, targeting 10 million first doses by mid-April.
